Hansoh Pharmaceutical (03692) Announces NMPA Approval of Second Indication for XinYue® (Inebilizumab Injection) for Adult Patients with IgG4-Related Disease

Hansoh Pharma (03692) announced on August 26, 2025, that its innovative drug Sinvo® (Inebilizumab Injection) (the product) has been granted a drug registration certificate by the National Medical Products Administration (NMPA) of China, approving an additional indication: for use in adult patients with Immunoglobulin G4-Related Disease (IgG4-RD). This is the second approved indication for Sinvo®, which was included in the NMPA’s priority review and approval process on February 8, 2025.